OncoMatch/Clinical Trials/NCT03993106
A Study of sEphB4-HSA in Kaposi Sarcoma
Is NCT03993106 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies sEphB4-HSA for kaposi sarcoma.
Treatment: sEphB4-HSA — sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. The purpose of this study is to learn if sEphB4-HSA will decrease the number or size of Kaposi sarcoma lesions in people.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Performance status
ECOG OR KARNOFSKY 0–2
Prior therapy
Cannot have received: anti-neoplastic treatment for KS
Participants who have had anti-neoplastic treatment for KS (including chemotherapy, radiotherapy, local treatment including topical 5-FU, biological therapy or investigational therapy) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study OR those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
Cannot have received: local therapy of any KS-indicator lesion
Exception: unless the lesion has clearly progressed since that local treatment
Previous local therapy of any KS-indicator lesion unless the lesion has clearly progressed since that local treatment. Any prior local treatment to indicator lesions regardless of the elapsed time should not be allowed unless there is evidence of clear-cut progression of said lesion.
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,000/mcL; Platelets ≥ 75,000/mcL
Kidney function
Creatinine within normal institutional limit for the reference lab OR creatinine clearance ≥ 60 mL/min/1.73 m2 as calculated by Cockcroft-Gault formula for participants with creatinine levels above institutional normal.
Liver function
Total bilirubin ≤ 1.5 X ULN; AST (SGOT) / ALT (SGPT) ≤ 2.5 X ULN
Cardiac function
QTcF (Fridericia Correction Formula) > 480 ms on 2 out of 3 EKGs [excluded]; Cardiac related illnesses including, but not limited to: Symptomatic congestive heart failure (NYHA Grade III/IV), unstable angina pectoris, cardiac arrhythmia
Absolute neutrophil count ≥ 1,000/mcL; Platelets ≥ 75,000/mcL; Total bilirubin ≤ 1.5 X ULN; AST (SGOT) / ALT (SGPT) ≤ 2.5 X ULN; Creatinine within normal institutional limit for the reference lab OR creatinine clearance ≥ 60 mL/min/1.73 m2 as calculated by Cockcroft-Gault formula for participants with creatinine levels above institutional normal. QTcF (Fridericia Correction Formula) > 480 ms on 2 out of 3 EKGs [excluded]; Cardiac related illnesses including, but not limited to: Symptomatic congestive heart failure (NYHA Grade III/IV), unstable angina pectoris, cardiac arrhythmia
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- AIDS Healthcare Foundation · Beverly Hills, California
- CAN (Community AIDS Network) Community Health · Sarasota, Florida
- UT Southwestern Medical Center · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify